Coherus BioSciences Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Coherus BioSciences sono diminuiti a un tasso medio annuo di -33.5%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 11.9%.

Informazioni chiave

-33.5%

Tasso di crescita degli utili

-32.6%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	-11.9%
Rendimento del capitale proprio	n/a
Margine netto	-0.1%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15

Coherus: Will Its Chinese Gambit Fail?

May 27

Ripartizione dei ricavi e delle spese

Come Coherus BioSciences guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:CHRS Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	304	0	163	95
30 Jun 24	308	-29	172	102
31 Mar 24	302	-59	186	100
31 Dec 23	257	-238	186	106
30 Sep 23	211	-217	192	112
30 Jun 23	182	-264	193	129
31 Mar 23	183	-271	195	151
31 Dec 22	211	-292	198	199
30 Sep 22	239	-279	195	221
30 Jun 22	276	-230	190	229
31 Mar 22	304	-210	179	246
31 Dec 21	327	-287	170	363
30 Sep 21	364	-232	157	357
30 Jun 21	395	-165	149	342
31 Mar 21	443	-76	143	310
31 Dec 20	476	132	139	143
30 Sep 20	489	162	137	192
30 Jun 20	487	181	137	153
31 Mar 20	435	145	140	127
31 Dec 19	356	90	137	94
30 Sep 19	232	-12	135	0
30 Jun 19	121	-118	128	0
31 Mar 19	37	-185	110	0
31 Dec 18	0	-209	94	106
30 Sep 18	0	-196	75	0
30 Jun 18	0	-196	64	0
31 Mar 18	1	-208	67	0
31 Dec 17	2	-238	69	0
30 Sep 17	2	-265	69	0
30 Jun 17	165	-122	69	0
31 Mar 17	178	-137	59	0
31 Dec 16	190	-127	52	0
30 Sep 16	199	-104	47	0
30 Jun 16	44	-259	44	0
31 Mar 16	37	-248	41	0
31 Dec 15	30	-223	36	0
30 Sep 15	26	-200	30	0
30 Jun 15	35	-137	24	0
31 Mar 15	33	-103	19	0
31 Dec 14	31	-87	16	0
30 Sep 14	26	-73	14	0
30 Jun 14	10	-86	12	0
31 Mar 14	6	-70	10	0
31 Dec 13	3	-54	7	0

Guadagni di qualità: CHRS al momento non è redditizia.

Margine di profitto in crescita: CHRS al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: CHRS non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 33.5% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di CHRS nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: CHRS non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: Le passività di CHRS superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Coherus BioSciences Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Lead Independent Director exercised options to buy US$139k worth of stock.

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 12%

New major risk - Share price stability

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.3% to US$12.88

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Price target decreased by 7.6% to US$12.11

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Price target decreased by 12% to US$13.63

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Price target decreased by 13% to US$15.56

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Consensus revenue estimates fall by 13%

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.09 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

High number of new and inexperienced directors